Emcure Pharmaceuticals shareholders approved all eight resolutions proposed at its 45th Annual General Meeting held on September 21, 2026. The meeting, conducted via video conferencing, ratified the final dividend of ₹3.60 per share and confirmed key board appointments.

The consolidated voting results, filed with stock exchanges on September 23, 2026, indicate strong support for most agenda items. However, the reappointment of Mr. Satish Mehta as Managing Director and Chief Executive Officer witnessed significant opposition from public institutions, although it ultimately passed with a 94.06% majority in favour.

Voting Results Summary

The scrutinizer’s report confirms that all ordinary and special resolutions were duly approved by members with the requisite majority. The table below summarizes the key voting outcomes for major agenda items:

Board and Governance Updates

The AGM transacted several ordinary and special resolutions regarding director appointments and auditor remuneration:

• Retirement of Mr. Berjis Desai as Chairman and Non-Executive Non-Independent Director upon conclusion of the AGM.
• Reappointment of Dr. Mukund Gurjar as Whole-time Director for a further period of one year commencing August 28, 2026.
• Reappointment of Mr. Satish Mehta as Managing Director & Chief Executive Officer for a further period of five years commencing April 1, 2027.
• Appointment of Mr. Raghu Kumar as an Independent Director for a first term of three consecutive years with effect from August 6, 2026.
• Ratification of remuneration payable to the Cost Auditor for FY27.

Mr. Berjis Desai chaired the proceedings before stepping down as Chairman and Non-Executive Non-Independent Director. His retirement was formally noted and approved by the members. Ms. Amruta Yangalwar, Company Secretary and Compliance Officer, managed the meeting logistics and e-voting process.

What the Numbers Show

The voting data reveals a divergence between promoter support and institutional sentiment regarding leadership continuity. While promoters voted unanimously in favour of all resolutions, public institutions cast 51.09% of their votes against the special resolution to reappoint Mr. Satish Mehta as MD & CEO. Despite this substantial institutional dissent, the resolution passed comfortably due to the overwhelming promoter holding, which constitutes approximately 77.8% of the total shares voted on that item.

In contrast, the final dividend declaration received 100% support from all categories of shareholders, indicating no disagreement on capital return policy. The clean passage of financial statement adoption and auditor ratification further underscores stable compliance standards for FY26.

Emcure Pharmaceuticals has scheduled a physical meeting with institutional investors in Pune on September 4, 2026. The company confirmed that no unpublished price-sensitive information will be discussed during the session.

Meeting details

The engagement is part of the company's compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Officials from Emcure will interact directly with a group of institutional investors.

The schedule is tentative and subject to change due to exigencies on the part of the investors or the company. The disclosure was made pursuant to Para A of Part A of Schedule III of the SEBI regulations.